Luxist Web Search

Search results

1. Results From The WOW.Com Content Network

2. Galena Biopharma - Wikipedia

   en.wikipedia.org/wiki/Galena_Biopharma

   Merger with Sellas Life Sciences. In 2017, Galena Biopharma Inc. announced a merger "with privately-held oncology company Sellas Life Sciences Group Ltd. in an all-stock transaction." The combined company was Sellas Life Science Group. The newly merged companies focused on the development of novel treatments for cancer.

3. Sellas' Ovarian Cancer Candidate Shows Clinical Benefit In ...

   www.aol.com/news/sellas-ovarian-cancer-candidate...

   SELLAS Life Sciences Group Inc (NASDAQ: SLS) announced topline data from its Phase 1/2 trial of galinpepimut-S (GPS) in WT1(+) relapsed or refractory platinum-resistant advanced metastatic ovarian ...

4. One Thing To Remember About The SELLAS Life Sciences ... - AOL

   www.aol.com/news/one-thing-remember-sellas-life...

   If you own shares in SELLAS Life Sciences Group, Inc. (NASDAQ:SLS) then it's worth thinking about how it contributes... One Thing To Remember About The SELLAS Life Sciences Group, Inc. (NASDAQ:SLS ...

5. Liminal BioSciences - Wikipedia

   en.wikipedia.org/wiki/Liminal_BioSciences

   Liminal BioSciences' aim to develop best or first-in-class therapies targeting indications with significant unmet needs, where a novel small molecule approach may be better suited using its drug discovery platform, specialized know-how and data-driven development plans. Liminal BioSciences is a development stage biopharmaceutical company ...

6. Life Sciences Institute - Wikipedia

   en.wikipedia.org/wiki/Life_Sciences_Institute

   The Life Sciences Institute (LSI) is a collaborative, multidisciplinary research institution located on the campus of the University of Michigan in Ann Arbor.It encompasses 27 faculty-led teams from 13 schools and departments throughout U-M. The LSI brings together leading scientists from a variety of life science disciplines, working with a range of models systems and cutting-edge research ...

7. J&J's medical device sales fall short, cancer drugs seen growing

   www.aol.com/j-j-beats-first-quarter-102244419.html

   J&J raised the low end of its 2024 forecast by 5 cents and now expects an adjusted profit of $10.60 to $10.75 per share. It also increased its quarterly dividend by 4.2% to $1.24 per share.